论文部分内容阅读
Ｓｏｌｖａｙ公司的Ｆｌｕｖｏｘａｍｉｎｅ是一种选择性５ＨＴ再摄取抑制剂（ＳＳＲＩ），１９９９年４月Ｆｌｕｖｏｘａｍｉｎｅ作为第一个ＳＳＲＩ类抗抑郁药在日本获准上市。日本健康和福利部（ＭＨＷ）已同意该药用于抑郁症和强迫症的治疗。Ｆｌｕｖｏｘａｍｉｎｅ是由
Solvay’s Fluvoxamine is a selective 5-HT reuptake inhibitor (SSRI). In April 1999, Fluvoxamine was approved as the first SSRI antidepressant in Japan. Japan’s Ministry of Health and Welfare (MHW) has agreed to use the drug for the treatment of depression and obsessive-compulsive disorder. Fluvoxamine is made from